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Abstract
Mathematical models of cholera and waterborne disease vary widely in their structures, in terms of transmission
pathways, loss of immunity, and a range of other features. These differences can affect model dynamics, with
different models potentially yielding different predictions and parameter estimates from the same data. Given
the increasing use of mathematical models to inform public health decision-making, it is important to assess
model distinguishability (whether models can be distinguished based on fit to data) and inference robustness
(whether inferences from the model are robust to realistic variations in model structure).
In this paper, we examined the effects of uncertainty in model structure in the context of epidemic cholera,
testing a range of models with differences in transmission and loss of immunity structure, based on known
features of cholera epidemiology. We fit these models to simulated epidemic and long-term data, as well as
data from the 2006 Angola epidemic. We evaluated model distinguishability based on fit to data, and whether
the parameter values, model behavior, and forecasting ability can accurately be inferred from incidence data.
In general, all models were able to successfully fit to all data sets, both real and simulated, regardless
of whether the model generating the simulated data matched the fitted model. However, in the long-term
data, the best model fits were achieved when the loss of immunity structures matched those of the model
that simulated the data. Two transmission and reporting parameters were accurately estimated across all
models, while the remaining parameters showed broad variation across the different models and data sets.
Forecasting efforts were not successful early in the outbreaks, but once the epidemic peak had been achieved,
most models were able to capture the downward incidence trajectory with similar accuracy.
Our results suggest that we are unlikely to be able to infer mechanistic details from epidemic case data
alone, underscoring the need for broader data collection, such as immunity/serology status, pathogen dose
response curves, and environmental pathogen data. Nonetheless, with sufficient data, conclusions from
forecasting and some parameter estimates were robust to variations in the model structure, and comparative
modeling can help to determine how realistic variations in model structure may affect the conclusions drawn
from models and data.
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1 Introduction
Cholera is a waterborne disease caused by the bacterium Vibrio cholerae, which manifests as severe
diarrhea and vomiting leading to dehydration. Left untreated, cholera can be up to 50% fatal, but
rehydration treatment can greatly reduce case fatality rates to as low as 1% [1,2]. Worldwide, cholera
causes three to five million cases and over 100,000 deaths per year [3]. Numerous mathematical
models of cholera transmission have been proposed to investigate factors that impact the dynamics
and transmission of waterborne diseases [4–13], and the ongoing cholera epidemic in Haiti has
spurred additional interest in the subject [12,14–18].
Due to the range of indirect transmission pathways and timescales, which may be represented by
environmental water sources, household water containers, foodborne transmission, and more [19,20],
commonly used mathematical models for cholera vary widely in their level of detail, spatial scale,
and model structure. Some models use a single term to represent a composite set of transmission
mechanisms, while others include multiple timescales of transmission [4, 8]. In addition to standard
mass-action transmission [8, 14], many models use nonlinear transmission functions for waterborne
transmission [4, 21] to reflect the dose response for cholera in the water. Models may also include
an asymptomatic transmission pathway, a hyperinfectious state for the bacteria immediately after
shedding, and other ecological and environmental factors in the environmental reservoir, such as
effects of vibriophages, plankton, weather, and climate [4–6,8, 10,18,22–26].
In addition to the variation in transmission mechanisms, loss of immunity to cholera is poorly
understood and therefore, modeled with many different assumptions. Estimates of the length
of immunity in the literature range widely from several months to three to ten years [6, 27, 28].
Immunity to cholera is of particular interest given the recent and ongoing oral cholera vaccine
campaigns worldwide, including in Haiti, Bangladesh, and Thailand [29–32], which raise additional
questions of how vaccine-derived immunity compares to immunity derived from infection.
As modeling gains prevalence among policy makers in public health [16, 33–37], comparative or
ensemble modeling approaches have been increasingly viewed as a way to ensure that the results of
parameter estimation, forecasting efforts, and the evaluation of intervention strategies are conserved
across the range of realistic model structures [38,39]. Two related concepts are useful to consider in
these efforts—model distinguishability addresses whether candidate models can be distinguished by
their fits to empirical data [40], and inference robustness assessments examine whether conclusions
drawn from a particular model are robust to realistic variations in the model structure [38]. Both of
these concepts are important to evaluate in the model-building process when model results are used
as the basis for decision making. The importance of parameter and model uncertainty for cholera
has been highlighted by several recent studies, both in general [26, 41], and in the context of the
recent Haiti epidemic specifically [25,41].
In this paper, we examine the effects of uncertainty in model structure on cholera disease
dynamics and inference by considering five models with different transmission and loss of immunity
mechanisms. The models under consideration share a common base, the SIWR model of Tien and
Earn [8]. The SIWR model is an extension of the classic Susceptible-Infected-Recovered (SIR) [42]
with an added compartment for pathogen concentration in an aquatic reservoir (W) [8]. In addition
to the person-to-person and water transmission pathways of the base SIWR model, we evaluate
two additional transmission-related features: a nonlinear Hill-function dose response for waterborne
transmission and an asymptomatic infection and transmission pathway [4,6,24,43]. We also consider
three loss of immunity features not included in the SIWR model: exponential loss of immunity,
stage-progression gamma-distributed loss of immunity, and a novel model that features progressively
increasing susceptibility after recovery from infection.
Using these five deterministic SIWR-based models, we first simulate data from each model with
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different types of added noise. In the frame of model distinguishability and inference robustness
assessment, we estimate model parameters and fit model data for all five models to each simulated
dataset and an empirical dataset from the 2006 cholera epidemic in Angola. We determine how well
each model recaptures the underlying parameter and R0 values, as well as how each model fits to
simulated data generated from different models. Finally, we forecast trajectories using parameters
estimated from truncated simulated incidence data and compare model forecasts with that of the
true simulated data.
2 Methods
2.1 Model descriptions
Here we introduce the five models of epidemic cholera disease dynamics that were used in our analyses.
We base these models on the SIWR model of Tien and Earn [8], which includes two timescales
of transmission: a fast, direct route (represented by βI) which incorporates direct person-person
transmission, foodborne and household transmission, and other non-environmental transmission
pathways; and a slow, indirect route (βW ) which represents long-term transmission mediated by
bacteria in the water. The scaled non-dimensional model equations are given by [8]:
s′ = µ− βIsi− βW sw − µs
i′ = βW sw + βIsi− γi− µi
w′ = ξ(i− w)
r′ = γi− µr
(1)
where s, i, and r represent the fractions of the population that are susceptible, infectious, and
recovered, respectively. The w variable is proportional to the concentration of V. cholerae in
the environment, and ξ represents the decay rate of the pathogen in the water (noting that the
nondimensionalization in [8] rescales the water so that the parameter for pathogen shedding into
the water is canceled and replaced with ξ, yielding the form of w seen above—see Supplementary
Information for nondimensionalization details). Parameter definitions and values are given in Table
1. The basic reproduction number (R0) for the baseline model includes both transmission pathways
and is given by
R0 = βI + βW
γ + µ
, (2)
where γ is the recovery rate and µ is the natural death rate in the population. The five models in
our study build upon this baseline SIWR model (Figure 1), with the aim of capturing a range of
features commonly considered in loss of immunity and cholera dynamics. These features include:
loss of immunity following exponential or gamma distributions, nonlinear dose response effects on
transmission, and asymptomatic cases.
To connect these models with data, we use the same measurement equation of y = κi (i.e. data
are assumed to have mean y with some measurement error), as has been used with a range of
data sets using the SIWR model [14, 18, 20] (including the same epidemic dataset as considered
here). The parameter κ represents a combination of factors including the reporting rate, at-risk
population size, potentially the infectious period (if used as an approximation for incidence data),
and potentially the symptomatic fraction (depending on the model considered), among others. We
define k = 1/κ and fit k rather than κ as this constrains the parameter estimation to be within
(0, 1) rather than (1,∞), making k easier to estimate [20].
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Figure 1: Diagrams of study models. First row (left to right): Exponential model, Dose Response
model, Asymptomatic model. Second row (left to right): Gamma model and Waning Immunity model.
Red compartments represent the infected population and red arrows represent person-person transmission.
Blue compartments represent pathogen concentration in water while blue arrows represent pathogen-person
transmission. Black compartments are susceptible or partially susceptible, while white compartments are
immune. Grey arrows indicate pathogen shedding.
Exponential model. The Exponential model builds on the baseline SIWR model by enabling
recovered individuals to return to the susceptible state. We assume those in the recovered class (r)
become susceptible (s) again after losing their immunity with rate parameter α. The duration of
immunity among recovered individuals follows an exponential distribution. R0 for this model has
the same structure as that of the baseline model (Eq. 2). The equations are given by:
s′ = µ− βIsi− βW sw − µs+ αr
i′ = βW sw + βIsi− γi− µi
w′ = ξ(i− w)
r′ = γi− µr − αr.
(3)
Dose Response model. The Dose Response model adds to the Exponential model by accounting
for nonlinear dose response effects in the waterborne transmission pathway [4, 41, 43, 44]. Challenge
studies in which volunteers ingested cholera and other pathogens at various doses have shown
that the probability of transmission is a nonlinear function of dose size, with sigmoidal or Hill
function-shaped curves that show low probabilities of infection at low concentrations and saturating
probability of infection once the bacteria attain sufficiently high concentrations in the aquatic
reservoir. Following previous studies, this model incorporated a Hill function dose response curve
in the parameter for waterborne transmission [4, 43]. We assume susceptible individuals become
infected at a rate βWmaxwK+w , where βWmax is the maximum force of infection from the water and K is
the concentration of V. cholerae that gives a 50% chance of water-transmitted cholera infection. As
in the Exponential model, individuals lose immunity at a rate α. The model equations are given by:
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s′ = µ− βIsi− βWmaxw
K + w
s− µs+ αr
i′ =
βWmaxw
K + w
s+ βIsi− γi− µi
w′ = ξ(i− w)
r′ = γi− µr − αr
(4)
and R0 for this model is given by:
R0 =
βI +
βWmax
K
γ + µ
.
Asymptomatic model. This model expands upon the Exponential model to include an asymp-
tomatic infection pathway. Estimates of the ratio of asymptomatic to symptomatic cholera infections
range from 3 to 100 [6]. We assumed 20% of infections were symptomatic (q = 0.2) [41]. We assumed
that all pathogens decay at the same rate ξ, regardless of which class they are shed from. Shedding
rates differ by symptomatic/asymptomatic status [41], with differential shedding rates σS and σA.
Scaling by these shedding rates and the other model parameters in the nondimensionalization (given
in the Supplementary Information) results in the following model equations:
s′ = µ− βIAsiA − βISsiS − βW sw − µs+ αArA + αSrS
i′S = q(βW sw + βISsiS + βIAsiA)− γiS − µiS
i′A = (1− q)(βW sw + βISsiS + βIAsiA)− γiA − µiA
w′ = ξ(iA + iS − w)
r′S = γiS − µrS − αSrS
r′A = γiA − µrA − αArA
(5)
where R0 for this model is given by:
R0 =
1
γ + µ
[q(βIS + βW ) + (1− q)(βIA + βW )] .
Gamma model. As opposed to exponential loss of immunity, the Gamma model represents waning
immunity through a chain of n recovered classes, which results in an immunity duration that has a
gamma distribution (See [45] and [46] for examples). The number of classes depends on the assumed
distribution on length of immunity; a greater number of compartments yields a duration that begins
to approximate a time delay. In this model, individuals in the chain of recovered classes retain
complete immunity until they return to the susceptible class, with equations given by:
s′ = µ− βIsi− βW sw − µs+ nαrn
i′ = βW sw + βIsi− γi− µi
w′ = ξ(i− w)
r′1 = γi− µr1 − nαr1
...
r′n = nαrn−1 − µrn − nαrn
(6)
and R0 for this model is same as Equation 2. We note that the progression through each stage
of immunity is at rate nα, so that this model has the same overall duration of immunity as the
previous models.
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Waning Immunity model. Given the wide range of estimates for the length of immunity in
cholera, we also developed a new model that allows for progressively increasing susceptbility after
infection over time. This may more realistically reflect the dynamics of loss of immunity, which is
likely to be progressive rather than switch-like. Similar models of progressive waning has been used
in a range of other contexts [47], and a distribution of cholera antibody titers are often observed in
cholera vaccine studies [48]. The Waning Immunity model again represents loss of immunity through
a chain of n classes, but individuals are at least partially susceptible at all points in the chain. The
transmission rates are given as functions of location in the chain (Figure 1), where more recently
recovered individuals are less likely to become infected. As individuals progress through the chain,
immunity to water-borne and person-person infection wanes, with susceptibility given by functions
f and g, respectively. The forms of f and g were chosen so that the probability of infection is close
to zero for individuals in the first susceptible class (sn) and equal to one for individuals in the last
susceptible class (s0). The model equations are:
i′ =
n∑
k=1
βIsi · g(k) +
n∑
k=1
βW sw · f(k)− γi− µi
w′ = ξ(i− w)
s′1 = µ+ nαs2 − βIs1i− βW s1w − µs
...
s′k = nαsk+1 − nαsk − βIg(k)ski− βW f(k)skw − µsk
...
s′n = γi− nαsn − βIg(n)sni− βW f(n)snw − µsn,
(7)
where we take f(k) = e−u1(k−1)/(n−1) and g(k) = e−u2(k−1)/(n−1). For simplicity, we assumed
baseline values of u1 = u2 = n, i.e. equal rates of waning immunity for waterborne and direct
transmission. This form was chosen to make f and g equal to 1 for sn and near zero for s1. We also
make the same adjustment to the waning immunity rates as in the Gamma model. Again, R0 for
this model is given by Equation 2.
2.2 Data simulation and baseline parameters
Model parameters were taken from previous modeling and empirical studies of epidemic cholera,
primarily from the estimates in [20], which used a SIWR model fitted to the 2006 outbreak of cholera
in Angola (Table 1). However, some updates to the parameter values were made, based on literature
estimates and known biology, as described in more detail in the Supplementary Information (Section
6.2). For the epidemic scenarios, we simulated six sets of data from each model to represent several
possible combinations of measurement error assumptions—noise-free, normal noise (µ = model
output, σ = 0.1× data), and poisson noise (λ = model output), and simulation durations—epidemic
(100 days) and long-term (3 years). Throughout the paper, we use the term simulation model to
refer to the model that simulated the data for the analysis. These 30 simulated datasets (five models
× three noise options × two simulation durations) were used for both parameter estimation/model
fitting and forecasting.
We used the average life expectancy of Angola, 55 years [49], to determine µ. Length of immunity
to cholera (α) acquired after infection is not well understood, with estimates ranging from weeks
to months to years [6, 27,28]. For our simulated data, we assumed immunity lasted one year. The
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complete set of values, descriptions, and sources for the baseline parameters used for data simulation
is given in Table 1.
While most parameters were common across models, some models required additional, specialized
parameters. For the Asymptomatic model, we chose βIA and βIS such that βIS was four times
greater than βIA and the weighted average of βIA and βIS (where symptomatic infections represent
q = 20% of the infected population) was equal to βI for all of the other models. To compare βI
across models, in the Results for the Asymptomatic model we report this weighted average of the
two transmission parameters. Reasoning that individuals with symptomatic infections will have
longer lasting immunity than those with asymptomatic infections, we assumed that immunity from
symptomatic infections (αS) would last two years and immunity from asymptomatic infections (αA)
would last 0.5 years. Similarly, the reported estimates of α for this model are given as the weighted
average of αS and αA. Additionally, the k value used for the Asymptomatic model was adjusted
based on the fact that only symptomatic cases are observed (Table 1), although the unadjusted
form was reported to facilitate model comparison in the Results.
The Dose Response model parameter structure also deviated from the other models, with the
waterborne transmission term expanded to form a Hill function. The half-saturation constant, K,
was determined based on previous literature estimates [50]. To determine the value of the maximum
transmission level, βWmax, there are in general several natural ways that one might match up the
Hill function with the single waterborne transmission parameter βW value used in the original
SIWR model. For example, one might match this value to the linear approximation of the Hill
function (i.e. let βW = βWmax/K, which approximates the Hill function for low values of w), or
to the maximum level of waterborne transmission (i.e. let βW = βWmax), or to some intermediate
value of transmission. The Dose Response model behaved quite similarly to the Exponential model
when the linear approximation was used; we chose the saturated, maximum value of transmission
to match the models, letting βWmax = βW for our baseline parameters, in order to accentuate the
differences between models.
For the simulated data, we assumed simulation model initial conditions with 1% of the population
infected and the remaining population susceptible. For the Asymptomatic model, we assumed
that 0.2% of the population was IS , 0.8% of the population was IA, and the remaining population
was susceptible. All model simulations and parameter estimation were done in MATLAB. We
also evaluated the baseline R0 for each model using the baseline parameter values—with these
parameters, all models have an R0 of 3, except for the Dose Response model, which has an R0 of 6.
2.3 Identifiability of parameters
Identifiability and uncertainty quantification methods allow us to address whether, and with
what degree of certainty, it is possible to uniquely recover the parameters of a model for a given
dataset. In general, two broad classes of identifiability are often considered—structural and
practical identifiability [53]. Structural identifiability addresses whether it is possible to estimate the
parameters based purely on the structure of the model and the measurements, typically assuming a
best-case of perfect, noise-free data. Practical identifiability considers how the amount and quality
of the data (e.g. level of measurement error, number of replicates) may affect estimation of the
parameters. One commonly used method of evaluating identifiability is via the Fisher Information
Matrix (FIM), a symmetric matrix that represents the amount of information about the parameters
that is contained in the data [54,55]. The rank of the FIM corresponds to the number of (locally
structurally) identifiable parameters, and taking the inverse of the FIM gives an approximation
of the covariance matrix for the parameters using the Cramer-Rao bound [53, 54, 56, 57]. We
calculated the FIM for each model (assuming the same parameters and starting parameters as for
7
Table 1: Model parameters. Additional details about the baseline values for each parameter are given in
Section 2.2 and the Supplementary Information (SI).
Parameter Description Value Units Source Models
µ natural birth/death rate in An-
gola
1
(55∗365) days
−1 [51] All
γ 1/(mean duration of infectious-
ness), or recovery rate
1
4 days
−1 [2, 14,20,52] All
βI person-person transmission rate 0.25 days
−1 [8, 14,20] All except
Asymptomatic
βIA person-person transmission rate
in asymptomatics
5
32 days
−1 See Model Description,
Section 2.2
Asymptomatic
βIS person-person transmission rate
in symptomatics
5
8 days
−1 See Model Description,
Section 2.2
Asymptomatic
βW water-borne transmission rate 0.50 days
−1 [8, 14,20] All
α loss of immunity rate 1365 days
−1 [6,27,28], See Section 2.2 All except
Asymptomatic
αIA loss of immunity rate in asymp-
tomatics
1
182.5 days
−1 See Section 2.2 Asymptomatic
αIS loss of immunity rate in symp-
tomatics
1
730 days
−1 See Section 2.2 Asymptomatic
ξ decay rate of cholera in water 1100 days
−1 [14, 20] All
k 1/(population at risk · reporting
rate)
1
50,000 people
−1 [20], See Section 2.2, SI All except
Asymptomatic
k proportion symptomatic cases /
(population at risk · reporting
rate)
0.2
50,000 people
−1 [20], See Section 2.2, SI Asymptomatic
K bacteria concentration that gives
50% chance of infection
0.4 unitless [50], See Model Descrip-
tion, Section 2.2
Dose Response
u1 modifies the susceptibility of in-
dividuals to direct infection
10 unitless See Model Description Waning Immu-
nity
u2 modifies the susceptibility of in-
dividuals to waterborne infection
10 unitless See Model Description Waning Immu-
nity
the simulated data, with daily data for one year), and evaluated both the rank and covariance
matrix. From the parameter variances, we calculated the percent coefficient of variation (%CV )
to evaluate parameter uncertainty. The %CV takes into account the size of the parameter value
when evaluating uncertainty, with %CV =
σp
p × 100 (where σp is the standard deviation and p is
the value of the parameter). We used a tolerance value [58], where %CV ≤ 100 indicates parameter
identifiability. Typically, structurally unidentifiable parameters will have extremely large (e.g.,
numerically near-infinite, typically > 106 [58]) %CV s, while practically unidentifiable parameters
have finite but large %CV s.
2.4 Parameter estimation and model fitting
Using maximum likelihood estimation and Nelder-Mead optimization in MATLAB, we fit each of the
five model structures to the 30 simulated datasets. When fitting our models to data, we estimated
all parameters except the birth/death rate, µ, and the recovery rate, γ, which are known [14,49,52].
Throughout the paper, we use the term fitting model to refer to the model that was used to fit an
epidemic dataset. To perform model fitting and parameter estimation from the simulated data,
we used two sets of parameters to initialize the optimization: informed starting parameters, which
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were the true parameters from the simulation model (i.e. the parameters used in generating the
simulated data, given in Table 1), and naive starting parameters, which were randomly chosen at
±20% of the true parameters. To compare model fits to simulated data, we calculated and compared
Akaike information criterion (AIC) values for the models [59]; for ease of comparison, we report
∆AIC values, defined as the difference in AIC between the model of interest and the best fit model
(i.e., model with the lowest AIC) for a given dataset. To compare parameter estimates among the
fitting models, we examined the percent deviation from the true value, which was calculated as the
difference between the estimate and the true value, divided by the true value. In this descriptive
analysis, a deviation less than 20% of the true value was considered ‘accurately recaptured’ because
the variation should be smaller than the potential deviation in starting parameters. Additional
details on the parameter estimation methods are also given in the Supplementary Information.
For model initial conditions when fitting, we let i(0) = kz(0), where z(0) is the initial data
value, and then assumed the remaining population to be susceptible. For the Asymptomatic model,
we assumed that the observed infected were symptomatic, and generated an additional fraction of
asymptomatically infected individuals based on the proportionality parameter q (with the remainder
of the population again assumed susceptible).
2.5 Forecasts of epidemic data
In addition to parameter estimation, we evaluated the ability for the study models to forecast
epidemic trajectories when provided with truncated and noisy simulated epidemic data. Using
10, 30, and 50 days of simulated incidence data (out of 100-day simulated epidemic data) with
normal noise from the five study models, we estimated parameters from each fitting model. These
parameter estimates were then used to generate a trajectory forecast for the remainder of the
100-day epidemic. Throughout the study, we use forecasting model to refer to the model used to
estimate these parameters and generate the forward-looking trajectory. For the parameter estimates
in this section, we used the informed starting values.
2.6 Application to 2006 cholera outbreak in Angola
We investigated the ability for the five study models to fit and forecast data from an empirical cholera
epidemic. We applied the same methods of parameter estimation, model fitting, and forecasting
to data from the recent 2006 cholera outbreak in Angola (data courtesy of the WHO Cholera
Task Force), shown in Figure 6. The outbreak began in Luanda province (February 13, 2006),
and eventually spread to 16 of 18 provinces, resulting in 82,204 cases and 3,092 deaths [20, 60].
The ‘true’ parameter values are unknown, so we considered both the ‘informed’ and ‘naive’ sets of
starting parameter values used in the simulated data for fitting to real data as well. In this case,
the ‘informed’ starting parameter values of course do not represent the true parameter values, but
are in some sense more ‘informed’, as the baseline values given in Table 1 are based on the best fit
parameters for the the original SIWR model to this data set in [20]. For fitting, we used weighted
least squares assuming a weight of σ2 = data [20]. The same initial condition setup was used in
these fits as for fitting to the simulated data.
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Table 2: Estimated %CV for each parameter. A %CV > 100 means that the parameter is practically
unidentifiable. A ‘-’ means that the parameter is not applicable to the model.
Parameters Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.016 0.019 - 0.011 0.016
βIS - - 1.11× 1012 - -
βIA - - 1.11× 1012 - -
βW 0.56 0.27 0.13 0.34 0.48
α 0.34 0.094 0.11 0.23
αS - - 0.60 - -
αA - - 0.072 - -
ξ 0.66 0.33 0.097 0.37 0.55
k 0.025 0.0081 0.028 0.042 0.044
u1 - - - - 0.55
u2 - - - - 8.33
3 Results
3.1 Identifiability of parameters
The FIMs for all models except for the Asymptomatic model were full rank. All FIM’s were
numerically invertible, with the percent coefficients of variation (%CV s) shown in Table 2. Apart
from the aforementioned rank deficiency in the Asymptomatic model, all parameter %CV s were
small enough that the parameters would be considered structurally identifiable.
The Asymptomatic model was rank deficient by one, although it was still possible to numer-
ically invert the FIM, which showed that the direct transmission parameters for symptomatic
vs. asymptomatic transmission form an identifiable combination. To determine the form of the
identifiable combination, we simulated noise-free data using the Asymptomatic model as described
in the Data Simulation section, and then plotted the sum-of-squares goodness-of-fit surface across a
range of values of βIS and βIA, shown in Figure 2. We found a linear canyon which achieved the
same minimum goodness-of-fit as the true parameters, corresponding to a structurally identifiable
combination [58, 61]. The form of the identifiable combination was given by the sum of the two
transmission parameters, weighted by the proportion of symptomatic cases, q: βI = qβIS +(1−q)βIA .
If we fixed either βIA or βIS using the identifiable combination as a constraint, and re-calculated
the FIM, all %CV s were < 1.5%. Because the dynamics for the two infected compartments (iS
and iA) are the same up to a constant scaling factor, it is impossible to distinguish the proportion
of cases generated from one compartment vs. the other. Given these results, in our subsequent
analyses for the Asymptomatic model we report only this identifiable combination βI , rather than
the individual unidentifiable parameters βIS and βIA .
3.2 Parameter estimation and model fitting to epidemic data
For the 100-day simulation duration, across the three noise cases, all five models fit the simulated
data well (Figure 3 and Supplementary Figure S5). Nearly all model fits matched the simulated
noisy data closely throughout the trajectory, with few runs (strings of consecutive data points on
one side of the fit) of obviously correlated residuals. Correspondingly, the AIC values were nearly
indistinguishable across model fits, but the Exponential or Dose Response model fits consistently
had the lowest (i.e., best) numerical values in 25 out of 30 cases, while the Asymptomatic and
Waning Immunity model fits frequently matched or followed close behind (Supplementary Tables S1
- S6).
10
Figure 2: Goodness-of-fit surface for βIA and βIS in the Asymptomatic model, highlighting the identifiable
combination. The red line highlights the minimum sum of squares, which corresponds to an identifiable
combination given by the line qβIS + (1− q)βIA .
The true parameter values of direct transmission (βI) and measurement scaling (k) were recovered
much more accurately than the other parameters that were common across all models (Figure 4),
and neither of these parameters had identifiability issues in our study (Table 2) or a previous cholera
modeling study [20]. For βI , the magnitude in parameter estimate deviations across four of five
fitting models was under 20%; the Asymptomatic model under-estimated βI by 33% in one instance.
For k, the magnitude in parameter estimate deviations across three of five fitting models was under
20%; the Gamma model underestimated k by 21-22% in two instances and the Waning Immunity
model both underestimated and overestimated k with a deviation magnitude greater than 20%.
In congruence with a previous study [20], we found that βW and ξ formed a practically unidenti-
fiable combination in all models (Figure 4 and Supplementary Figure S1), which might explain their
large deviations from the true parameter value. We also considered that some of the deviations
in βW (and by extension ξ), may be due to the different choice of structure for βW in the Dose
Response model. We evaluated the parameter variation without the Dose Response parameter
estimates or simulated data, and found that while there was some attenuation of the more extreme
outliers for the estimates of βW across all models, βW still showed a much broader range than βI or
ξ, and the remaining parameter distributions remained largely identical (shown in Supplementary
Figure S1).
While most of the parameters were neither consistently underestimated nor overestimated by
any of the models, the estimates of α tended to be underestimated for both the Gamma and Waning
Immunity models when fitted to epidemic data (although other runs of estimation, e.g. using
different optimizer settings did not necessarily yield this). Deviations were systematically smaller
when models were fitting Exponential model data, and as expected, parameter estimate recapture
accuracy improved as simulated data decreased in noise (Figure S2). Parameter estimates for all
combinations of simulation model data and fitting models are reported in Supplementary Tables S1
- S6.
11
none normal poisson
lllllllllll
lllll
llll
lll
lll
lll
lll
lll
lll
lll
llll
llllll
llllllllllllllllllllllllllllllllllllllllllllllllll
lllllllll
llll
lll
ll
ll
ll
ll
ll
ll
ll
ll
ll
lll
llllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll
lllllllllll
lllll
llll
lll
lll
lll
lll
lll
lll
lll
llll
lllll
lllllllllllllllllllllllllllllllllllllllllllllllllll
lllllllllll
lllll
llll
lll
lll
lll
lll
lll
lll
llll
lllll
llllllllllllllllllllllllllllllllllllllllllllllllllllll
lllllllllll
lllll
llll
lll
lll
lll
lll
lll
lll
llll
lllll
llllllllllllllllllllllllllllllllllllllllllllllllllllll
llllllll
l
ll
lll
lllll
ll
l
ll
ll
l
lll
l
lll
l
l
l
l
ll
ll
l
l
l
ll
ll
ll
l
ll
l
lll
ll
l
ll
llll
ll
l
l
l
l
l
l
l
lllll
l
l
l
l
lllll
l
l
l
l
llll
ll
l
lllllll
lll
lll
lll
lll
lll
llll
l
l
ll
l
ll
l
ll
l
ll
l
l
l
l
l
l
ll
l
lll
l
l
l
l
ll
lll
l
ll
ll
l
l
lll
llll
l
l
lll
l
lllllllllllllllllllll
l
llll
lllll
lll
lllll
lll
lll
ll
ll
ll
l
ll
ll
l
l
l
llll
l
ll
l
ll
l
ll
ll
ll
ll
l
l
l
l
ll
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
llll
lll
l
lll
lll
ll
l
lll
ll
ll
llllllll
llllll
lll
l
l
ll
ll
ll
lll
lllll
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
ll
l
ll
l
l
l
ll
ll
ll
l
ll
l
l
l
l
l
lll
l
llll
l
l
l
lllll
l
l
l
l
ll
l
l
l
lll
ll
ll
ll
l
llll
ll
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
llll
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
ll
l
llllllllll
l
llll
ll
l
l
l
lllllll
lll
llll
lllll
ll
llll
llll
llll
lllll
ll
lll
lll
ll
lll
llllllllllll
l
lllllllllllllllllllllllllllllllllllll
lllllllll
llll
lll
ll
lll
lll
ll
ll
ll
ll
lll
ll
lllllllllllllllllll
lllllllllllllllllllllllllllllllllllllllllllll
llllllllll
llllll
llll
llll
lllll
lll
lll
ll
llll
llll
lll
llll
lllllll
ll
llllllllllllllll
l
lllllllllllllllllllllll
llllllllll
lllll
lllll
llll
ll
llll
lll
llll
llll
l
l
lll
lllllllll
lll
lll
llllllllllll
llllllllllllllllllllllllllll
llllllllll
lll
lllll
llll
lll
lll
llll
lll
ll
lllll
ll
llll
llllllllll
ll
llllllllllllllllll
lllllllllllllllllllllll
0
500
1000
1500
2000
2500
0
1000
2000
3000
4000
0
500
1000
1500
2000
2500
0
500
1000
1500
2000
2500
0
500
1000
1500
2000
2500
Exponential
D
ose R
esponse
Asym
ptom
atic
G
am
m
a
W
a
ning Im
m
u
nity
0 25 50 75 100 0 25 50 75 100 0 25 50 75 100
Time (days)
In
fe
ct
io
n 
In
ci
de
nc
e
fitting model Exponential Dose Response Asymptomatic Gamma Waning Immunity
true data l
Figure 3: Fits to 100-day simulated model data (indicated by row) without noise (left column), with normal
noise (middle column), and with poisson noise (right column), using naive starting parameters. Model fits
are overlaid, thus obscuring some of the model fits in the figure. All fitting models were able to capture the
mean epidemic data despite added noise and model misspecification.
3.3 Parameter estimation and model fitting to long-term data
For the 3-year data, all models were able to fit the qualitative dynamics of the simulated data, and
with a few exceptions, visually all models matched all data sets well (Supplementary Figures S6 and
S7). However, unlike the 100-day data, the lowest AIC values were most often achieved when the same
model which generated the data was used for fitting (though often other models yielded very close
AIC values, with differences ≤ 5). AIC values were consistently lower when models where the waning
immunity distributions matched those of the data simulation model (exponentially-distributed
waning immunity: Exponential, Dose Response, and Asymptomatic models; gamma-distributed
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waning immunity: Gamma and Waning Immunity models) (Supplementary Tables S7 - S12).
Similarly, estimates from models where the waning immunity distributions matched those of the
data simulation model were more accurate (Supplementary Figure S4). We note that our ability
to distinguish model fits through large differences in AIC was facilitated by the large volume of
simulated data—daily data over three years. In practice, time series data would be much sparser,
making it more difficult to distinguish the different models.
The parameter estimate accuracy did not appear to differ strongly as a function of the type
of added noise (Supplementary Figure S4). As with the 100-day data analyses, βI was the most
accurate estimated parameter across all models, followed by k, although k estimates appeared to be
biased when the waning immunity distribution of the data simulation model did not match that of
the fitting model (Figure 4, Supplementary Tables S7 - S12). In general, α was underestimated
for gamma-distributed waning models fitted to exponentially-distributed waning models, and
overestimated in the reverse case. The effect of the practically identifiable combination between βW
and ξ was also present in the 3-year data, with underestimates of βW tending to be compensated by
overestimates of ξ (Figure 4, Supplementary Tables S7 - S12).
3.4 Forecasts from simulated epidemic data
Epidemic trajectories were projected forward based on 10, 30, and 50 days of observed, simulated
normal noise data for each study model. All forecasting models generated trajectories that were
poorly representative of the true simulated data when only 10 or 30 data points were observed (Figure
5). In particular, even when forecasting models matched simulation models, these truncated epidemic
datasets did not allow for accurate forecasts. While forecasts generated from 30 observations as
compared to 10 observations were improved, performance remained poor overall, with only one out
of 25 forecasts able to accurately capture both the timing and magnitude of the simulated epidemic
peak (Exponential model forecasting from Dose Response simulated data). In fact, 11 of 25 forecasts
continued to project exponential growth upwards past the 100-day simulation period.
Forecasts generated from 50 observed data points were significantly improved, with 16 of 25
forecasts roughly capturing the downward trajectory of the true data. Notably, most models
underestimated the peak infection incidence and timing of the simulated Exponential model data,
and the Dose Response model forecasts were least able to capture the correct disease dynamics of
any model besides its own. As with the previous forecasts, a match between the simulation and
forecasting model did not necessarily generate the most accurate forecast.
3.5 Application to 2006 cholera outbreak in Angola
We now turn our attention to data collected from a 2006 cholera outbreak in Angola. The fits of
the models to the data are shown in Figure 6. The corresponding parameter estimates and AIC
values for these fits, accounting for both informed and naive starting parameters, are given in Table
3. All models fit the data well, with similar trajectories that captured the overall shape, peak, and
duration of the epidemic. The lowest %CV s were found in the parameters k and βW , for both
the ‘informed’ and ‘naive’ starting parameters (where ‘informed’ here indicates the values chosen
from the literature for data simulation, although these are not the true values as they were for the
simulated data). The Waning Immunity model gave the lowest AIC for both naive and informed
starting parameters (2940 and 2864, compared to AICs greater than 3400 for all other models),
suggesting that the Waning Immunity model provides the best fit of the Angola data. Interestingly,
this model showed very little direct transmission (βI), suggesting that waterborne transmission may
be enough to explain the outbreak.
13
βI βW α ξ k
l l l l l
l
l
l l
l l
l l
l l
l
l
l
l
l
l l l
l
l
−100
0
100
200
300
fitting model
pe
rc
en
t d
ev
ia
tio
n 
fro
m
 tr
u
e
 p
ar
a
m
e
te
r
Exponential Dose Response Asymptomatic Gamma Waning Immunity
parameter
βI βW α ξ k
l l l
l l
l
l
l l l l l
l
l
l
l l
l
l l
l l
l
l l
−100
0
100
200
300
fitting model
pe
rc
en
t d
ev
ia
tio
n 
fro
m
 tr
u
e
 p
ar
a
m
e
te
r
Exponential Dose Response Asymptomatic Gamma Waning Immunity
parameter
l
ll
l
l l
ll
l
l l
l l
l
l
l ll
l
l
l
l
l
l
l
l
l l
ll
l
l
l l
l
l
ll
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
lll
l
l
0.000
0.025
0.050
0.075
0.100
0.0 0.5 1.0 1.5 2.0 2.5
βW estimate
ξ e
st
im
at
e
fitting model l l l l lExponential Dose Response Asymptomatic Gamma Waning Immunity
Figure 4: Top: Percent deviation of estimates from true parameter values, grouped by parameter for the
simulated 100-day data (left) and the simulated 3-year data (right). The model used to fit the data and
estimate the parameter is indicated by color. The median across all estimates (i.e., across added noise type,
simulation model, and data duration) is marked with a black point in the distribution and the black dashed
line represents ±20% deviation. Distribution ranges for the βw, α, and ξ subplots are trimmed for visibility.
Bottom: Scatterplot of βW and ξ estimates by colored fitting model. Four data points in the distribution
tails are truncated for ease of viewing. See Supplementary Figure S1 for the full plot.
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Table 3: Parameter estimates for the 2006 Angola epidemic data.
(a) Informed starting parameters
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.1460 0.1981 0.1600 0.2629 0.0358
βW 0.6033 0.5055 0.6814 1.2485 1.0063
α 0.0051 0.0020 0.0028 0.000026 0.000048
ξ 0.0544 0.0148 0.0413 0.0074 0.0530
k 1.37e-5 1.30e-5 1.37e-5 1.13e-5 1.95e-5
AIC 3667 3679 3657 4311 2940
R0 3.00 5.85 3.03 6.04 4.17
(b) Naive starting parameters
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.1865 0.0655 0.1827 0.2629 3.5e-8
βW 0.8420 0.3101 0.7384 1.2479 0.9696
α 0.0029 0.0050 0.0021 0.00017 0.000089
ξ 0.0257 0.0651 0.0312 0.0074 0.0668
k 1.33e-5 1.36e-5 1.33e-5 1.13e-5 1.96e-5
AIC 3731 3431 3696 4311 2864
R0 4.11 3.36 3.68 6.04 3.88
Note: The average estimates across starting conditions for αS and αA for the Asymptomatic model were 2.61e-9 and
0.005, respectively.
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Figure 6: “Naive” (left) and “informed” (right) starting parameter fits to 2006 Angola epidemic data.
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4 Discussion
Mathematical modelers often need to make decisions on how to model transmission and loss immunity
mechanisms, so it is critical to understand the robustness and sensitivity of results to realistic
variations in model structures. Toward that end, we have examined how model uncertainty and
misspecification affect parameter estimates, model fits, and model forecasting ability. We considered
five deterministic SIWR-based model structures, each including different hypothesized mechanisms of
cholera transmission and loss of immunity, using both simulated data and data from the 2006 cholera
epidemic in Angola. We found that goodness-of-fit criteria were unable to distinguish misspecified
model fits from those of the true model for simulated epidemic data, and that forecasting from
short-term data of one month or less was universally poor, even when the model that generated the
data and the model that produced the forecast were the same. However, model fits for long-term data
were found to be specific to the type of waning immunity that was implemented (i.e., exponential-
vs. gamma-distributed waning immunity). Moreover, some parameters were consistently estimated
across all models and datasets, suggesting that it may be possible to estimate some parameters even
when the underlying mechanistic model is unknown.
We showed that each model was able to capture the epidemic trajectories for all datasets, real
and simulated, regardless of the source of the simulated data, type of noise, or starting parameters.
Indeed, often the best fit to a given epidemic dataset did not come from the model which generated
it. This suggests that it may not be possible to infer the true underlying mechanisms of loss of
immunity and transmission solely from epidemic cholera incidence or prevalence data. This highlights
the distinction between the issues of identifiability (parameter uncertainty) and distinguishability
(model uncertainty)—all model parameters were structurally identifiable (excepting the parameter
combination for the Asymptomatic model), but the model structure itself may not be possible to
infer from the data.
When a longer, 3-year data set was considered—as noted above, in this case it was generally
possible to distinguish exponentially-distributed waning models (Exponential, Dose Response, and
Asymptomatic) from gamma-distributed waning models (Gamma and Waning Immunity). Indeed,
the best-fit model to the simulated 3-year data was often the model which generated it, although
typically the other models with the same waning distribution had very similar AIC values (differences
≤ 5), such that the models may not be distinguishable in practice. Additionally, the simulations here
assumed frequent data taken daily, while more realistic data over three years would likely be weekly
or monthly, making distinguishabilty by goodness of fit even less likely. Nonetheless, these results
do suggest that some degree of model selection, at least for loss of immunity mechanisms, may be
possible with longer term data sets. Other additional data might add to the distinguishability of
realistic models, such as data on pathogen shedding, bacterial concentration in water sources, or
immunity/serology data such as antibody titers.
Our study design also enabled the systematic assessment of parameter estimates under conditions
of model misspecification. As noted above, all parameters were structurally identifiable (apart from
the identifiable combination for βIA and βIS), but unfortunately, identifiability analyses only inform
the validity of parameter estimates when the true underlying model is known. When we consider the
variation of the parameter estimates across different model misspecification scenarios, the picture is
more complex. As βI was recovered quite well for all simulated data sets, this suggests that the
“fast” transmission parameter and reporting rate/population factor may be accurately estimated
from any of the common SIWR model variants, even if the true underlying disease mechanisms are
unknown. Interestingly, k was more accurately recovered from the misspecified models when the
100-day data sets were used rather than the 3-year data (Figure 4), suggesting that when model
misspecification is present, more data may not always be better. It is likely that the bias in k was
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being used to help correct for fitting issues that came from using an incorrect model structure, but
this would be difficult to assess in practice with real data.
Previous work noted that in the SIWR model, βW and ξ became practically unidentifiable when
noisy data was considered, and formed a practically identifiable combination [20]. It was conjectured
there that this issue of practical identifiability may extend more broadly to many models that
include a waterborne or environmental transmission pathway. Indeed, here we confirmed that βW
and ξ are practically unidentifiable and form a practically identifiable combination across multiple
SIWR-based models. This underscores the need for improved data collection regarding waterborne
cholera transmission in order to better inform modeling and public health intervention efforts.
However, we note that while the two parameters were practically unidentifiable in all models, the
curve of the identifiable combination traced in Figure 4 was quite similar across all models and data
sets. This suggests that while these two parameters may be practically unidentifiable in all models,
their combination may be more tightly estimated across models and datasets, similarly to βI and k.
In part due to this practical unidentifiability of βW , estimates of R0 varied widely across all models,
both for the epidemic data in Angola and for all types of simulated data.
For the epidemic data, the estimates of α were uniformly underestimated for both the Gamma
and Waning Immunity models when fitted to epidemic data. This may be due to the fact that both
of these models have a gamma-distributed type of waning process, meaning that significant waning
would be unlikely to be observed over the 100-day epidemic period. This may have resulted in highly
insensitive α estimates for these two models, so that the optimization algorithm wandered to very
low values for α. In general, in the 3-year datasets, α was underestimated for gamma-distributed
waning models fitted to exponential waning models, and underestimated in the reverse case. This
may be because the gamma-distributed waning models used a slower loss of immunity to generate
the flat trajectories after the initial peak, while the exponential-distributed waning models may
have used a more rapid α to generate the subsequent peaks in the disease trajectory.
The new Waning Immunity model presented here had the best absolute fit to the Angola
epidemic data, but as previously noted, this does not necessarily indicate that the waning immunity
mechanism was the true driver of these epidemic dynamics. Longitudinal data on sequential
infections of cholera or on antibody titers over time are needed to validate the idea that recently
infected individuals regain susceptibility progressively after recovery. If waning immunity does
indeed best represent epidemic cholera dynamics, the parameter estimates in our study suggest
the hypothesis that the Angola epidemic was spread primarily by waterborne transmission; the
Waning Immunity model estimates for βI were at least two orders of magnitude smaller than those
for βW (and much smaller than in any other model). We note that this somewhat contradicts a
previous study using the base SIWR model, which showed stronger waterborne transmission but
still significant direct transmission [20].
Further work is needed to examine the ability for SIWR-based models to project epidemic
trajectories based on limited and noisy data early in an outbreak. Only projections that took place
after the epidemic peak appeared to capture any semblance of disease prevalence; projections were
also poor when the forecasting model matched the simulation model, perhaps suggesting that it
may not be possible to forecast accurately with deterministic SIWR models until the latter half of
the epidemic. This is to be expected in the very early part of the epidemic, during the exponential
growth phase, as during this phase the epidemic is largely linear on a log-scale and so can be
explained by only two parameters. This idea is borne out in other real-time forecasting efforts—for
example, efforts to forecast the trajectory of the 2014 Ebola epidemic in West Africa met with
difficulty [62–65]. We note that our results illustrate how agreement across a range of models
may not guarantee accuracy; however once the epidemic peak was observed, all models tended to
converge on similar and more accurate forecasts. This suggests that once sufficient data is obtained,
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forecasting is possible even if the model structures do not match the underlying mechanisms. Future
work may examine whether early outbreak forecasting, discrimination of model structures, and
inference from forecasting comparisons may be aided by additional data on weather and climate
variables such as rainfall or sea surface temperature [18,25,66–68].
There are several limitations and future directions for this work, to consider different model
structures, frameworks, and empirical datasets. Alternative cholera transmission mechanisms (such
as hyperinfectivity [5,10,22,24,69]), spatial structure [14,17,70,71], and climate drivers [18,25,66–68]
were also realistic features that could have been added to the suite of model structures we considered.
Model comparison with hyperinfectivity and two potential environmental reservoirs were considered
in study by Rinaldo et al. [25], using a larger, detailed spatial model of the 2010 Haiti cholera
epidemic (including human and pathogen movement, river networks, climate drivers, etc.). We also
did not evaluate our conclusions outside of the deterministic ODE framework, although partial
differential equation (PDE), agent-based, and stochastic models are also frequently used in similar
contexts [6, 68, 72, 73]. In addition, most of the parameter values were motivated from a single
outbreak dataset (Angola, 2006), and may not reflect the breadth of parameter space for cholera
epidemics. Additional work to further examine the identifiability, uncertainty of these models,
and to test alternative parameter estimation methods (e.g. Bayesian and/or global approaches)
would be warranted as well. It would also be useful to consider alternate data assumptions (e.g.
weekly or monthly data frequency, additional noise and error assumptions), and even to consider the
generalizability of these results to other infectious disease models. Further, here we only considered
the effects of model structure on parameter estimation and forecasting. Additional work could
use model comparison to evaluate the effects of model and parameter uncertainty on the optimal
control of interventions, similar to that proposed by Akman and Schaefer [26]. Their focus on the
optimal balance of vaccination and sanitation strategies may be particularly interesting, as the lack
of distinguishability between models may be less problematic if multiple models yield consistent
control strategies.
In conclusion, our study presents a systematic framework for the comparison of model mechanisms
and inference that can be applied broadly in infectious disease epidemiology. Modeling requires
simplifying assumptions to be an effective tool, but we show here that the choice of simplifications
can have significant effects on the parameter estimates, and that it may be difficult or impossible
to use fit to data as a criteria to distinguish between plausible simplified models. Of course, in
real-world contexts, there is unlikely to be a ‘true’ model in the sense that we considered in our
simulated data—instead, each of the models represents a simplification, albeit with realistic elements.
We note that our results also show that the most realistic model—a ‘super-model’ containing all
of the elements considered individually across the five models here—would almost certainly be
unidentifiable from case data alone. Public health decision makers desire tools that demonstrate
the sensitivity of results to model assumptions (on the analysis side) and policy decisions (on the
implementation side). Attempts to address the divide between decision maker needs and modelers’
ability to present useful, actionable information are on the rise, with the development of adaptive
management, cost-benefit, and game theoretic frameworks in public health [74–80]. In demonstrating
that goodness-of-fit is not sufficient to infer transmission and immunity mechanisms in a disease
system, and that some parameter estimation may be valid even when mechanisms remain elusive, we
similarly seek to inform modelers and decision makers about the relative utility of different analyses
for specific types of policy questions. Our research raises questions about the appropriateness and
equality of model structures and types for epidemiological inference, and future work should seek to
further characterize the sensitivity of public health decision making in the context of model choice.
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6 Supplementary Information
6.1 Dimensional and nondimensional forms of each model
As in [8, 20], we use the nondimensional forms for each model throughout in order to reduce issues
of model unidentifiability and simplify their presentation. Here we briefly introduce the dimensional
and nondimensional forms for each model. We begin with the original SIWR model of Tien and
Earn [8]. The dimensional form is given as:
S′ = µN − bWWS − bISI − µS
I ′ = bWWS + bISI − γI − µI
W ′ = σI − ξW
R′ = γI − µR
(8)
with constant population N = S + I +R. Here bW represents the rate at which susceptibles become
infected due to contact with pathogen in the water (W ), bI is the transmission parameter for direct
transmission, σ is the rate that infected individuals shed pathogen into the water, ξ the rate of
decay of pathogen in the water, γ the recovery rate, and µ the population turnover rate. We
nondimensionalize the model by letting s = S/N , i = I/N , r = R/N , w = ξσNW , βI = bIN , and
βW = bWNσ/ξ:
s′ = µ− βW sw − βIsi− µs
i′ = βW sw + βIsi− γi− µi
w′ = ξ (i− w)
r′ = γi− µr
(9)
The Exponential model can be nondimensionalized using the same scaling as given for the SIWR
model (since it is the same model but with an added loss of immunity term). Similarly, an equivalent
scaling can be used for the Gamma and Waning Immunity models, with rj = Rj and sj = Sj for
j = 1, . . . , n, for each model respectively.
For the Dose Response model, the dimensional form of the model is given by:
S′ = µN − bISI − bWmaxW
K˜ +W
S − µS + αR
I ′ = bISI +
bWmaxW
K˜ +W
S − γI − µI
W ′ = σI − ξW
R′ = γI − µR− αR
(10)
To nondimensionalize, we take s = S/N , i = I/N , r = R/N , w = ξσNW , and βI = bIN as before,
but now we take K = ξσN K˜ and simply let βWmax = bWmax, yielding the final form given in (4).
(We note that there are other options for nondimensionalization, e.g. letting w = W/K˜, but for
consistency with the other models we opted for this.)
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Lastly, for the Asymptomatic model, the dimensional form of the model is given by:
S′ = µN − bWWS − bISSIS − bIASIA − µS
I ′S = q(bWWS + bISSIS + bIASIA)− (γ + µ)IS
I ′A = (1− q)(bWWS + bISSIS + bIASIA)− (γ + µ)IA
W ′ = σSIS + σAIA − ξW
R′S = γIS − µRS
R′A = γIA − µRA
(11)
The nondimensionalization is similar to the previous, except that we note that IS and IA are at a
fixed ratio to one another, with the fraction q of all infections being symptomatic and 1− q being
asymptomatic. This is because the infected initial conditions and the new cases are both at this
ratio, and both equations have the same loss rates (γ + µ). Thus we take I = IS + IA, and write
W ′ = (qσS + (1 − q)σA)I − ξW . Then let σ = (qσS + (1 − q)σA), and we can take an analogous
rescaling as for the SIWR model above, letting s = S/N , iS = IS/N , iA = IA/N , rS = RS/N ,
rA = RA/N , w =
ξ
σNW , βIS = bISN , βIA = bIAN , and βW = bWNσ/ξ. This rescaling yields the
final model given in (5).
6.2 Baseline parameter values and estimation details
As noted in the Methods section, we made a few modifications of the original parameters for the
SIWR model fitted to the Angola epidemic, based other studies in the literature. We increased the
value of the pathogen decay rate ξ to 1/100 days (pathogen lifetime approximately three months),
to better match the faster decay rates measured in other studies [4, 14, 81, 82]. As ξ and βW form a
practically identifiable combination (Figure S1) [20], we also reduced βW from 1 [20] to 0.5, which
resulted in approximately the same epidemic shape and gave similar values for both waterborne
and direct transmission parameters. The values of βI and k were based on previous Angola data
estimates [20], with k adjusted after our changes to βW and ξ to make roughly the same size
epidemic as in [20].
Additionally, for parameter estimation, we found that in the normal noise case, maximum
likelihood (i.e. weighted least squares) often yielded poor performance when the simulation model
did not match the fitting model (e.g. Gamma fitted to Asymptomatic data). As the true underlying
error distribution would not be known a priori, we instead fitted using weighted least squares with
a weight of σ2 = data, as suggested in [20] and used for fitting the Angola data here. This gives
a balance between weighted (where σ2 would be proportional to (data)2) and unweighted least
squares (where the weights are proportional to (data)0, i.e. constant weighting). We also note that
for the Angola data, the prevalence measurement equation used is only an approximation for the
weekly incidence data (similar to previous studies [18,20]). However the approximation was quite
close, with a total (cumulative) error of 1% over the entire epidemic (simulating weekly incidence
vs. using the prevalence approximation using the default parameters).
6.3 Parameter estimation results
6.3.1 100-day epidemic data
In addition to pooling parameter estimate deviations across parameters (Figure 4), we also grouped
them by the model used to generate the data and the type of noise added to the simulated data
(Figure S2). No data simulation model enables better recapture of parameter estimates, but the
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Figure S1: Scatterplot of βW and ξ estimates by colored fitting model with all data points (left) and without
Dose Response model estimates and fits (right).
Exponential and Dose Response models had notably smaller deviations from the true parameter when
fitting their own simulated data. In addition, the Gamma and Waning Immunity models recaptured
true parameter values from the Gamma simulated data well (less than 10% deviation). Median
deviations from the true parameter remained relatively constant across added noise categories,
but deviations tended to be smaller with less noise, as evidenced by the longer lower tails of the
distributions in the ‘None’ and ‘Poisson’ panels. As model complexity in the dimension of loss
of immunity increased, the absolute deviation for the loss of immunity parameter (α) decreased
(Figure S3).
6.3.2 3-year long-term data
In examining the pooled parameter estimates for the simulated 3-year data, we found that parameter
estimates were more accurate when models fit to data generated from models with the same
distribution of waning immunity (exponentially-distributed waning immunity: Exponential, Dose
Response, and Asymptomatic models; gamma-distributed waning immunity: Gamma and Waning
Immunity models) (Figure S4). There were no discernible patterns in parameter estimate accuracy
among added noise types (Figure S4). We also note that for the case of the Gamma Model fitted to
data from the Exponential model, the convergence criterion for optimization had to be increased to
ensure convergence.
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Figure S2: Percent deviation of parameter estimates from true values, grouped by model used to simulate the
initial data (left) and type of noise added to data (right) for the simulated 100-day data. The model used to
fit the data and estimate the parameter is indicated by color. The median across all estimates (i.e., across
added noise type and simulation data) is marked with a black point in the distribution and the black dashed
line represents ±20% deviation. Distribution ranges are truncated for visibility.
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Figure S3: Absolute percent deviation of parameter estimates on a log scale, grouped by parameter. The
model used to fit the data and estimate the parameter is indicated by color.
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Figure S4: Percent deviation of parameter estimates from true values, grouped by model used to simulate the
initial data (left) and type of noise added to data (right) for the simulated 3-year data. The model used to
fit the data and estimate the parameter is indicated by color. The median across all estimates (i.e., across
added noise type and simulation data) is marked with a black point in the distribution and the black dashed
line represents ±20% deviation. Distribution ranges are truncated for visibility.
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6.4 Model fits to simulated epidemic (100-day) data
Shown below are the model fits for all simulating model datasets with informed starting parameters
(Figure S5).
———————————————
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Figure S5: Fits to simulating model data (indicated by row) without noise (left column), with normal noise
(middle column), and with poisson noise (right column), using informed starting parameters. Model fits are
overlaid, thus obscuring some of the model fits in the figure.
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6.5 Model fits to simulated long-term (3-year) data
Shown below are the model fits for all simulating model datasets with informed starting parameters
(Figure S6) and naive starting parameters (Figure S7).
———————————————
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Figure S6: Fits to simulating model data (indicated by row) without noise (left column), with normal noise
(middle column), and with poisson noise (right column), using informed starting parameters. Model fits are
overlaid, thus obscuring some of the model fits in the figure.
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Figure S7: Fits to simulating model data (indicated by row) without noise (left column), with normal noise
(middle column), and with poisson noise (right column), using naive starting parameters. Model fits are
overlaid, thus obscuring some of the model fits in the figure.
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6.6 Parameter estimate tables to simulated epidemic data
We report the estimates for common model parameters to all 100-day simulated data fits in Tables
S1 through S6. Across all fits with the Asymptomatic model, the mean and standard deviation of
αS and αA were 0.002 (SD = 0.001) and 0.004 (SD = 0.005), respectively. The reported estimates
of α for this model are given as the weighted average of αS and αA (as described in the methods).
Table S1: Noise-free with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2494 0.2517 0.2494 0.2560 0.2505
βW 0.1809 0.5414 0.4131 1.0600 0.6476
α 0.0030 0.0017 0.0027 2.47e-06 4.69e-05
ξ 0.0113 0.0034 0.0124 0.0038 0.0075
k 1.96e-05 2.03e-5 1.99e-5 1.83e-5 2.02e-5
∆AIC 0 0 4 15 4
R0 1.72 6.42 2.65 5.26 3.59
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2506 0.2500 0.2480 0.2780 0.2449
βW 1.0709 0.5000 0.6989 1.4200 1.0399
α 0.0030 0.0027 0.0026 4.94e-06 3.46e-05
ξ 0.0117 0.0100 0.0191 0.0055 0.0131
k 2.02e-5 2.00e-5 2.00e-5 1.74e-5 2.10e-5
∆AIC 0 0 4 220 7
R0 5.28 6.00 3.79 6.79 5.14
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2496 0.2503 0.2500 0.2590 0.2594
βW 0.3979 0.2308 0.5000 0.6680 0.6680
α 0.0050 0.0043 0.0034 2.84e-05 2.96e-05
ξ 0.0129 0.0085 0.0100 0.0053 0.0053
k 1.97e-5 1.97e-5 2.00e-5 1.62e-5 1.62e-5
∆AIC 0 0 3 40 38
R0 2.59 3.31 3.00 3.71 3.71
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2480 0.2494 0.2489 0.2500 0.2500
βW 0.3139 0.3510 0.4596 0.5000 0.4998
α 0.0011 1.54e-9 0.0012 3.09e-05 3.21e-05
ξ 0.0175 0.0057 0.0113 0.0100 0.0100
k 1.96e-5 2.08e-5 2.03e-5 2.00e-5 2.00e-5
∆AIC 0 1 4 5 4
R0 2.25 4.51 2.83 3.00 3.00
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2484 0.2495 0.2489 0.2500 0.2500
βW 0.3390 0.2716 0.4617 0.5000 0.5000
α 0.0008 3.37e-9 0.0013 3.09e-05 3.58e-05
ξ 0.0159 0.0074 0.0112 0.0100 0.0100
k 1.97e-5 2.04e-5 2.03e-5 2.00e-5 2.00e-5
∆AIC 0 0 4 5 4
R0 2.35 3.71 2.84 3.00 3.00
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Table S2: Noise-free with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2494 0.2503 0.2506 0.2560 0.2502
βW 0.4159 0.2186 0.6352 1.0800 0.5607
α 0.0031 0.0025 0.0024 6.54e-05 2.35e-05
ξ 0.0124 0.0090 0.0076 0.0037 0.0088
k 1.99e-5 1.96e-5 2.01e-5 1.83e-5 2.00e-5
∆AIC 0 0 4 15 4
R0 2.66 3.19 3.54 5.34 3.24
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2488 0.2438 0.2514 0.2780 0.2477
βW 0.7729 0.2353 1.3799 1.4300 1.6883
α 0.0033 0.0033 0.0024 5.06e-05 4.94e-05
ξ 0.0170 0.0247 0.0088 0.0055 0.0076
k 2.00e-5 1.92e-5 2.04e-5 1.74e-5 2.27e-5
∆AIC 0 0 4 220 5
R0 4.09 3.33 6.52 6.83 7.74
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2491 0.2512 0.2507 0.2600 0.2601
βW 0.3934 0.3603 0.6118 0.4370 0.4339
α 0.0052 0.0037 0.0032 3.7e-05 3.33e-05
ξ 0.0133 0.0052 0.0079 0.0080 0.0081
k 1.99e-5 2.00e-5 2.00e-5 1.56e-5 1.56e-5
∆AIC 0 0 3 51 49
R0 2.57 4.61 3.45 2.79 2.78
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2499 0.2494 0.2484 0.2500 0.2497
βW 0.4943 0.4224 0.4910 0.5780 0.4483
α 2.74e-5 2.30e-8 0.0018 2.22e-05 2.47e-05
ξ 0.0102 0.0047 0.0107 0.0086 0.0113
k 2.00e-5 2.11e-5 2.06e-5 2.03e-5 1.99e-5
∆AIC 9 11 0 16 14
R0 2.98 5.22 2.96 3.31 2.79
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2499 0.2494 0.2485 0.2500 0.2501
βW 0.5005 0.8094 0.5234 0.5680 0.4476
α 9.66e-6 1.78e-8 0.0016 3.58e-05 3.83e-05
ξ 0.0100 0.0024 0.0100 0.0088 0.0112
k 2.00e-5 2.17e-5 2.07e-5 2.03e-5 1.98e-5
∆AIC 0 3 5 7 5
R0 3.00 9.09 3.09 3.27 2.79
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Table S3: Normal Noise with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2395 0.2384 0.2364 0.2480 0.2436
βW 0.2816 0.1160 0.2298 0.7500 0.8582
α 0.0040 0.0040 0.0044 1.23e-05 4.44e-05
ξ 0.0215 0.0213 0.0294 0.0060 0.0059
k 1.96e-5 1.92e-5 1.96e-5 1.86e-5 2.07e-5
∆AIC 0 0 0 23 11
R0 2.08 2.11 1.86 3.99 4.41
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2677 0.2677 0.2679 0.2890 0.2660
βW 0.8064 0.3931 0.8161 1.3700 2.1494
α 0.0026 0.0022 0.0018 2.47e-06 3.09e-05
ξ 0.0136 0.0110 0.0133 0.0053 0.0050
k 1.93e-5 1.90e-5 1.93e-5 1.71e-5 2.01e-5
∆AIC 0 1 5 109 16
R0 4.30 5.00 4.34 6.63 9.66
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2212 0.2274 0.1658 0.2420 0.2420
βW 0.2825 0.2013 0.1927 0.5050 0.5047
α 0.0091 0.0061 0.0138 3.58e-05 3.46e-05
ξ 0.0297 0.0136 0.1446 0.0093 0.0093
k 2.15e-5 2.15e-5 1.98e-5 1.67e-5 1.67e-5
∆AIC 42 58 0 124 126
R0 2.01 2.92 1.43 2.99 2.99
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2792 0.2811 0.2803 0.2810 0.2806
βW 0.1144 0.1017 0.1470 0.4290 0.4279
α 0.0051 0.0011 0.0027 5.19e-05 2.22e-05
ξ 0.0250 0.0092 0.0174 0.0055 0.0055
k 1.70e-5 1.64e-5 1.66e-5 1.68e-5 1.68e-5
∆AIC 0 9 8 14 12
R0 1.57 2.14 1.71 2.84 2.83
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2568 0.2562 0.2623 0.2640 0.2642
βW 0.1184 0.0638 0.5149 0.5060 0.5034
α 0.0067 0.0054 0.0014 4.32e-05 1.98e-05
ξ 0.0446 0.0317 0.0072 0.0068 0.0068
k 1.72e-5 1.79e-5 1.90e-5 1.80e-5 1.80e-5
∆AIC 0 2 11 17 12
R0 1.50 1.66 3.11 3.08 3.07
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Table S4: Normal Noise with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2373 0.2418 0.2417 0.2480 0.2483
βW 0.2515 0.1836 0.4272 0.4700 0.7331
α 0.0048 0.0026 0.0023 2.72e-05 2.22e-05
ξ 0.0258 0.0119 0.0129 0.0097 0.0060
k 1.97e-5 1.98e-5 2.02e-5 1.79e-5 1.88e-5
∆AIC 0 7 10 25 22
R0 1.95 2.80 2.68 2.87 3.92
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2670 0.2689 0.2679 0.2890 0.2647
βW 0.6610 0.6375 0.7955 1.3700 0.7846
α 0.0028 0.0021 0.0018 6.54e-05 1.6e-05
ξ 0.0171 0.0065 0.0137 0.0052 0.0148
k 1.91e-5 1.94e-5 1.92e-5 1.71e-5 1.98e-5
∆AIC 0 2 5 109 23
R0 3.71 7.45 4.25 6.63 4.20
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2052 0.2282 0.2248 0.2430 0.2278
βW 0.1888 0.1954 0.3747 6.7300 0.5668
α 0.0132 0.0058 0.0064 3.7e-05 2.35e-05
ξ 0.0697 0.0138 0.0199 0.0007 0.0119
k 1.99e-5 2.11e-5 2.21e-5 1.84e-5 2.24e-5
∆AIC 0 45 42 101 44
R0 1.58 2.87 2.40 27.89 3.18
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2805 0.2811 0.2772 0.2810 0.2801
βW 0.3507 0.0878 0.9213 0.3640 0.5275
α 0.0004 0.0015 0.0013 4.07e-05 3.09e-05
ξ 0.0068 0.0107 0.0031 0.0064 0.0046
k 1.69e-5 1.63e-5 1.89e-5 1.66e-5 1.72e-5
∆AIC 0 0 9 6 4
R0 2.52 2.00 4.79 2.58 3.23
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2532 0.2608 0.2578 0.2640 0.2642
βW 0.1279 0.0798 0.1455 0.5050 0.5038
α 0.0083 0.0030 0.0054 3.33e-05 2.47e-05
ξ 0.0470 0.0208 0.0338 0.0068 0.0068
k 1.86e-5 1.76e-5 1.81e-5 1.80e-5 1.80e-5
∆AIC 0 7 6 19 14
R0 1.52 1.84 1.61 3.08 3.07
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Table S5: Poisson Noise with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2494 0.2494 0.2497 0.2550 0.2554
βW 0.4999 0.1967 0.5043 0.6140 0.6139
α 0.0025 0.0024 0.0022 3.7e-05 2.47e-05
ξ 0.0100 0.0101 0.0098 0.0067 0.0067
k 1.98e-5 1.94e-5 1.97e-5 1.78e-5 1.78e-5
∆AIC 0 0 4 141 9
R0 3.00 2.96 3.02 3.48 4.48
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2479 0.2496 0.2496 0.2810 0.2508
βW 0.7228 0.4984 0.9517 0.8190 8.9934
α 0.0035 0.0028 0.0024 2.59e-05 0.000312
ξ 0.0185 0.0101 0.0134 0.0093 0.0013
k 2.01e-5 2.01e-5 2.03e-5 1.69e-5 2.11e-5
∆AIC 0 0 4 2504 4
R0 3.88 5.98 4.80 4.40 36.97
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2238 0.2433 0.2412 0.2550 0.2556
βW 0.1752 0.1922 0.4279 0.5990 0.6030
α 0.0140 0.0052 0.0049 3.58e-05 4.57e-05
ξ 0.0608 0.0117 0.0140 0.0063 0.0063
k 2.06e-5 2.04e-5 2.14e-5 1.63e-5 1.63e-5
∆AIC 0 7 9 411 40
R0 1.60 2.89 2.68 3.42 3.43
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2541 0.2531 0.2528 0.2540 0.2541
βW 0.4763 0.7484 0.6401 0.5030 0.5028
α 3.00e-8 1.00e-8 0.0011 3.09e-05 2.96e-05
ξ 0.0099 0.0025 0.0076 0.0094 0.0094
k 1.97e-5 2.14e-5 2.08e-5 1.98e-5 1.99e-5
∆AIC 0 2 5 108 4
R0 2.92 8.49 3.57 3.03 3.03
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2576 0.2573 0.2582 0.2590 0.2592
βW 0.4043 0.1973 0.2819 0.2570 0.2568
α 3.00e-8 4.74e-9 0.0011 1.48e-05 3.46e-05
ξ 0.0112 0.0092 0.0161 0.0171 0.0171
k 1.92e-5 1.93e-5 1.84e-5 1.77e-5 1.77e-5
∆AIC 22 25 24 0 24
R0 2.65 3.00 2.16 2.06 2.06
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Table S6: Poisson Noise with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2497 0.2509 0.2491 0.2550 0.2552
βW 0.5188 0.4631 0.4233 0.6130 0.6067
α 0.0023 0.0015 0.0025 2.72e-05 3.21e-05
ξ 0.0096 0.0040 0.0120 0.0067 0.0068
k 1.98e-5 2.00e-5 1.96e-5 1.78e-5 1.78e-5
∆AIC 0 0 4 141 9
R0 3.07 5.63 2.69 3.47 3.45
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2493 0.2501 0.2511 0.2790 0.2409
βW 0.8864 0.5567 1.4445 1.4300 0.7726
α 0.0033 0.0028 0.0027 0.000159 4.07e-05
ξ 0.0146 0.0089 0.0085 0.0054 0.0191
k 2.02e-5 2.02e-5 2.05e-5 1.74e-5 2.14e-5
∆AIC 0 0 4 2504 9
R0 4.54 6.57 6.78 6.83 4.05
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2274 0.2444 0.2402 0.2550 0.2348
βW 0.1813 0.5314 0.3553 0.5950 0.2995
α 0.0130 0.0046 0.0048 0.000138 2.47e-06
ξ 0.0535 0.0040 0.0175 0.0064 0.0254
k 2.06e-5 2.17e-5 2.13e-5 1.63e-5 3.90e-5
∆AIC 0 7 8 411 7
R0 1.63 6.29 2.38 3.40 2.14
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2538 0.2531 0.2519 0.2540 0.2540
βW 0.6268 0.1305 0.2467 0.5030 0.5058
α 8.97e-8 0.0006 0.0015 1.73e-05 2.96e-05
ξ 0.0076 0.0153 0.0216 0.0094 0.0093
k 2.03e-5 1.88e-5 1.91e-5 1.98e-5 1.99e-5
∆AIC 0 1 5 108 4
R0 3.52 2.32 1.99 3.03 3.04
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning Immunity
βI 0.2592 0.2587 0.2582 0.2590 0.2591
βW 0.2472 0.0913 0.2548 0.2560 0.2582
α 0.0001 0.0003 3.58e-5 2.47e-05 1.48e-05
ξ 0.0179 0.0198 0.0179 0.0171 0.0171
k 1.77e-5 1.71e-5 1.81e-5 1.77e-5 1.78e-5
∆AIC 20 20 24 0 24
R0 2.03 1.95 2.05 2.06 2.07
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6.7 Parameter estimate tables to simulated long-term data
We report the estimates for common model parameters to all simulated 3-year data fits in Tables S7
through S12. The reported estimates of α for this model are given as the weighted average of αS
and αA (as described in the methods).
Table S7: Noise-free with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.25 0.2485 0.25 0.2843 0.2862
βw 0.5 0.2019 0.4997 0.855 0.5586
ξ 0.01 0.0102 0.01 0.0003 0.0003
α 0.0027 0.0027 0.0027 0.0013 0.001
k 2e-05 1.9838e-05 2e-05 7.091e-06 7.045e-06
∆AIC 0 2 2 5621 2663
R0 4.7041 4.686 2.9994 1.8204 1.7454
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2541 0.25 0.2536 0.3174 0.3289
βw 1.2106 0.5 1.1845 0.2998 0.0602
ξ 0.0098 0.01 0.0101 0.0022 0.0057
α 0.0028 0.0027 0.0028 0.0022 0.0017
k 2.0052e-05 2e-05 2.0075e-05 1.0406e-05 1.3733e-05
∆AIC 3 0 5 19378 4312
R0 1.2408 1.2184 1.2986 2.9994 2.9852
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2641 0.2638 0.25 0.2781 0.2806
βw 0.9121 0.3632 0.5 0.1771 0.1558
ξ 0.0037 0.0037 0.01 0.0035 0.0027
α 0.0028 0.0028 0.0047 0.0024 0.0018
k 1.7712e-05 1.7622e-05 2e-05 8.083e-06 9.176e-06
∆AIC 435 417 0 16535 12318
R0 2.9994 3.0124 2.9982 4.5562 3.3787
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2721 0.2845 0.272 0.25 0.2496
βw 0.0381 0.0081 0.0527 0.5 0.4968
ξ 0.0599 0.0406 0.0526 0.01 0.0101
α 0.0045 0.0044 0.0043 0.0027 0.0026
k 9.928e-06 8.969e-06 1.1052e-05 2e-05 2.0025e-05
∆AIC 3165 2363 2965 0 6
R0 5.8577 5.9988 5.751 2.4685 1.5559
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2841 0.2683 0.2762 0.2535 0.25
βw 0.0253 0.0261 0.0468 0.5338 0.5
ξ 0.0393 0.0518 0.0472 0.0087 0.01
α 0.0048 0.0045 0.0048 0.0028 0.0027
k 9.698e-06 1.186e-05 1.1116e-05 1.984e-05 2e-05
∆AIC 2016 2319 2467 53 0
R0 1.2374 1.3334 1.2919 3.1485 2.9994
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Table S8: Noise-free with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.25 0.2485 0.25 0.284 0.2859
βw 0.5 0.2019 0.4998 0.2011 0.4573
ξ 0.01 0.0102 0.01 0.0017 0.0005
α 0.0027 0.0027 0.0027 0.0016 0.0011
k 2.0001e-05 1.9839e-05 2.0001e-05 7.813e-06 9.256e-06
∆AIC 0 2 2 6335 3268
R0 4.704 4.6854 2.945 1.8204 7.485
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2541 0.25 0.2536 0.3174 0.3257
βw 1.2107 0.5 1.1845 0.2998 0.2044
ξ 0.0098 0.01 0.0101 0.0022 0.0013
α 0.0028 0.0027 0.0028 0.0022 0.0011
k 2.0051e-05 2e-05 2.0074e-05 1.0405e-05 9.781e-06
∆AIC 3 0 5 19378 4687
R0 1.2251 1.2184 1.2165 2.9995 2.9614
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2641 0.2638 0.2499 0.2781 0.2863
βw 0.9121 0.3631 0.4865 0.1771 1.5854
ξ 0.0037 0.0037 0.0103 0.0035 0.0002
α 0.0028 0.0028 0.0047 0.0024 0
k 1.7712e-05 1.7622e-05 2.0002e-05 8.083e-06 7.517e-06
∆AIC 435 417 0 16534 1088
R0 2.9994 3.0124 2.9985 1.94 2.9719
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.284 0.2845 0.2852 0.25 0.2481
βw 0.0224 0.0081 0.019 0.5 0.4924
ξ 0.0409 0.0406 0.0388 0.01 0.0106
α 0.0044 0.0044 0.0044 0.0027 0.0025
k 9.227e-06 8.968e-06 8.983e-06 2e-05 2.0306e-05
∆AIC 2348 2363 2374 0 15
R0 5.8579 5.9991 5.751 2.4685 2.12
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2843 0.2843 0.2818 0.2535 0.25
βw 0.0246 0.0096 0.0329 0.5338 0.4999
ξ 0.039 0.0395 0.0418 0.0087 0.01
α 0.0048 0.0048 0.0048 0.0028 0.0027
k 9.64e-06 9.495e-06 1.0268e-05 1.9839e-05 1.9997e-05
∆AIC 2015 2029 2036 53 0
R0 1.2353 1.2332 1.2586 3.1486 2.9993
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Table S9: Normal Noise with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2353 0.2333 0.2366 0.2797 0.2809
βw 0.6058 0.2456 0.5649 0.4866 0.8163
ξ 0.0095 0.0097 0.01 0.0004 0.0002
α 0.0027 0.0027 0.0027 0.0013 0.0009
k 2.0988e-05 2.0851e-05 2.0818e-05 6.297e-06 6.007e-06
∆AIC 19 0 35 5766 3140
R0 1.6652 4.5328 2.9955 1.9128 92.5967
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2643 0.2599 0.2628 0.3225 0.3304
βw 1.18 0.492 1.0925 0.328 0.4811
ξ 0.0098 0.0099 0.0108 0.0023 0.0005
α 0.0027 0.0027 0.0029 0.0023 0.0002
k 2.0178e-05 2.014e-05 2.0241e-05 1.1207e-05 1.0059e-05
∆AIC 13 0 0 20009 2408
R0 1.2759 1.2825 1.2786 2.9856 2.8721
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2888 0.2691 0.2545 0.2809 0.2827
βw 0.1276 0.3458 0.4945 0.1974 22.871
ξ 0.0044 0.0037 0.01 0.0033 0
α 0.0028 0.0028 0.0046 0.0024 0.0011
k 9.445e-06 1.7675e-05 2.0264e-05 8.613e-06 7.707e-06
∆AIC 374 356 0 17276 10728
R0 3.3636 3.388 3.2053 3.0646 4.388
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2832 0.2812 0.283 0.2547 0.2517
βw 0.0359 0.0158 0.0367 0.4918 0.4665
ξ 0.0413 0.044 0.0413 0.0099 0.0111
α 0.0042 0.0042 0.0042 0.0027 0.0026
k 1.0557e-05 1.0611e-05 1.0614e-05 2.0103e-05 2.0242e-05
∆AIC 2742 2815 2755 0 45
R0 5.7759 5.9579 5.4204 2.6017 3.2457
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2859 0.2569 0.2626 0.25 0.245
βw 0.0151 0.0376 0.0786 0.5541 0.521
ξ 0.0354 0.0531 0.0516 0.0087 0.0102
α 0.005 0.0044 0.0046 0.0028 0.0027
k 8.886e-06 1.3397e-05 1.3031e-05 2.021e-05 2.0479e-05
∆AIC 2370 2707 2550 82 0
R0 1.204 1.4036 1.3645 3.2159 3.0635
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Table S10: Normal Noise with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2534 0.2533 0.2519 0.2867 0.2882
βw 0.5183 0.1628 0.5081 3.2638 1.103
ξ 0.0095 0.0122 0.0101 0.0001 0.0002
α 0.0027 0.0029 0.0029 0.0012 0.0011
k 2.0344e-05 1.9617e-05 2.053e-05 7.543e-06 9.246e-06
∆AIC 0 290 85 5447 3114
R0 4.3526 4.1834 2.5527 1.8362 3.8392
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2584 0.2541 0.2577 0.3192 0.3259
βw 1.1856 0.4961 1.1703 0.2877 0.5982
ξ 0.0098 0.0099 0.01 0.0024 0.0004
α 0.0027 0.0027 0.0028 0.0023 0.0003
k 2.0184e-05 2.0149e-05 2.0215e-05 1.0794e-05 9.537e-06
∆AIC 0 29 3 18824 1699
R0 1.1697 1.2044 1.2238 2.9509 2.9878
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2706 0.271 0.2572 0.2789 0.2881
βw 0.8178 0.31 0.3811 0.1802 0.6719
ξ 0.0036 0.0037 0.012 0.0038 0.0005
α 0.0028 0.0028 0.0053 0.0026 0.0002
k 1.7532e-05 1.7274e-05 2.0013e-05 8.728e-06 8.285e-06
∆AIC 353 343 0 16973 612
R0 3.0864 2.6403 3.0393 14.199 5.5637
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2854 0.2811 0.2787 0.2444 0.2413
βw 0.0071 0.008 0.0273 0.4935 0.5058
ξ 0.0331 0.047 0.0487 0.0105 0.0108
α 0.0047 0.0045 0.0045 0.0028 0.0027
k 7.728e-06 8.714e-06 9.333e-06 2.0136e-05 2.035e-05
∆AIC 2671 2582 2560 33 0
R0 5.7748 5.9765 5.7108 2.4269 3.6956
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2698 0.283 0.2679 0.2455 0.2382
βw 0.053 0.0066 0.0575 0.5681 0.5225
ξ 0.0511 0.0408 0.052 0.0088 0.0109
α 0.0047 0.005 0.0047 0.0028 0.0028
k 1.1313e-05 8.693e-06 1.1565e-05 2.024e-05 2.0648e-05
∆AIC 2337 2375 2352 168 0
R0 1.291 1.1978 1.3013 3.254 3.0422
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Table S11: Poisson Noise with Informed Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2488 0.2474 0.2489 0.2844 0.2863
βw 0.5133 0.206 0.4902 1.3858 0.2994
ξ 0.0099 0.0102 0.0104 0.0002 0.0007
α 0.0027 0.0027 0.0028 0.0012 0.0011
k 2.0025e-05 1.9843e-05 1.9985e-05 7.016e-06 7.125e-06
∆AIC 0 1 7 5374 2609
R0 4.6086 4.6231 2.9614 1.8825 1.3443
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2513 0.2464 0.2505 0.3169 0.3237
βw 1.1872 0.4991 1.1563 0.3045 0.4892
ξ 0.0101 0.0102 0.0105 0.0021 0.0004
α 0.0028 0.0028 0.0028 0.0022 0.0003
k 2.0087e-05 2.0057e-05 2.0122e-05 1.0264e-05 9.359e-06
∆AIC 11 0 11 20616 2665
R0 1.2258 1.2116 1.2007 3.0071 3.0295
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.266 0.2656 0.2512 0.2789 0.2836
βw 0.8864 0.3562 0.4893 0.1918 0.0525
ξ 0.0037 0.0037 0.0102 0.0032 0.0064
α 0.0028 0.0028 0.0047 0.0024 0.0027
k 1.7647e-05 1.7562e-05 2.0051e-05 8.117e-06 7.422e-06
∆AIC 394 378 0 18262 10941
R0 3.0476 3.0491 2.9556 6.6794 2.3422
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2825 0.2843 0.2858 0.249 0.2484
βw 0.024 0.0075 0.0144 0.5029 0.5091
ξ 0.0432 0.0405 0.0367 0.01 0.01
α 0.0044 0.0045 0.0045 0.0027 0.0026
k 9.236e-06 8.761e-06 8.503e-06 2.0042e-05 2.0147e-05
∆AIC 2170 2169 2164 0 2
R0 5.7528 5.9758 5.626 2.4851 3.2509
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2851 0.2853 0.2816 0.2548 0.2518
βw 0.026 0.0099 0.0359 0.5329 0.505
ξ 0.0386 0.0388 0.0429 0.0087 0.0098
α 0.0048 0.0047 0.0047 0.0028 0.0027
k 9.763e-06 9.56e-06 1.0457e-05 1.979e-05 1.9935e-05
∆AIC 1928 1945 2050 42 0
R0 1.244 1.2401 1.2699 3.1503 3.0263
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Table S12: Poisson Noise with Naive Starting Parameters
(a) Exponential Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2552 0.2537 0.255 0.2859 0.2878
βw 0.4554 0.1836 0.4444 0.7224 0.8403
ξ 0.0103 0.0106 0.0107 0.0004 0.0002
α 0.0028 0.0028 0.0028 0.0013 0.0009
k 1.9629e-05 1.9456e-05 1.9629e-05 7.409e-06 7.356e-06
∆AIC 0 9 1 5977 2642
R0 4.9052 4.8738 3.1952 1.822 3.9554
(b) Dose Response Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2506 0.2464 0.2469 0.3163 0.3236
βw 1.211 0.4997 1.0985 0.2978 0.1002
ξ 0.0099 0.0101 0.0115 0.0022 0.0046
α 0.0028 0.0028 0.003 0.0023 0.0023
k 2.0143e-05 2.0092e-05 2.0322e-05 1.0274e-05 1.0532e-05
∆AIC 17 0 6 21009 7592
R0 1.2193 1.2534 1.2365 3.0394 3.0231
(c) Asymptomatic Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2601 0.2598 0.2444 0.2773 0.285
βw 0.9665 0.3836 0.5545 0.1783 0.704
ξ 0.0037 0.0037 0.0096 0.0033 0.0004
α 0.0028 0.0028 0.0046 0.0024 0.0003
k 1.7987e-05 1.7883e-05 2.0388e-05 7.794e-06 7.128e-06
∆AIC 553 533 0 17627 1233
R0 2.8416 2.8505 2.7973 4.0324 4.5113
(d) Gamma Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2844 0.2687 0.2819 0.2492 0.2483
βw 0.0205 0.0179 0.0273 0.5109 0.5076
ξ 0.0403 0.0647 0.0437 0.0099 0.0101
α 0.0044 0.0044 0.0044 0.0027 0.0026
k 9.013e-06 9.971e-06 9.507e-06 2.0071e-05 2.0105e-05
∆AIC 2263 3144 2301 0 6
R0 5.8454 5.9808 5.3806 2.4558 1.6952
(e) Waning Immunity Data
Parameters/AIC Exponential Dose Response Asymptomatic Gamma Waning
βi 0.2843 0.2864 0.283 0.2539 0.2508
βw 0.0249 0.0069 0.027 0.5327 0.5013
ξ 0.039 0.0351 0.0408 0.0087 0.0098
α 0.0048 0.0048 0.0049 0.0028 0.0027
k 9.613e-06 8.931e-06 9.775e-06 1.9806e-05 1.9943e-05
∆AIC 2051 2062 2112 42 0
R0 1.2365 1.2149 1.2398 3.1458 3.0077
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